694 results on '"Bracarda, Sergio"'
Search Results
202. Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.
203. TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC)—Liquid biopsy for biomarkers discovery.
204. Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).
205. Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
206. PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA
207. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
208. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer
209. A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent
210. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis
211. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation
212. Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies’ agenda
213. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
214. Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies
215. Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused
216. Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.
217. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
218. Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial
219. Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors
220. Prostate changes related to therapy: with special reference to hormone therapy
221. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting
222. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
223. Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.
224. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer
225. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
226. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
227. GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
228. Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.
229. Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).
230. Poor Survival in Prostate Cancer Patients with Primary Refractoriness to Docetaxel
231. Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.
232. Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.
233. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
234. Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey
235. Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer
236. The treating scenario in genitourinary oncology: what is new? Part 2
237. The Treating Scenario in Genitourinary Oncology: What is New? Part 1
238. Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).
239. Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).
240. Relationship between biomarkers and everolimus efficacy in the phase III RECORD-1 trial of patients with metastatic renal cell carcinoma (mRCC).
241. Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.
242. Reply from Author re: Axel Bex. Interferon-α in Combination with Sorafenib: RAPSODY or Requiem? Eur Urol 2013;63:262–4
243. Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY)
244. Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
245. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
246. Biologic tools to personalize treatment in genitourinary cancers
247. Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group
248. Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey.
249. PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).
250. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.